Metabolon provides metabolomics and lipidomics solutions that support life‑science research, diagnostics, therapeutic development, and precision medicine applications. Its platform includes a Global Discovery Panel enabled by a proprietary metabolomics reference library and scalable, customizable multiomics offerings that span discovery through clinical trials and product life‑cycle management. The company cites more than 20 years of activity, 10,000+ projects, and 3,000+ publications, and holds ISO 9001:2015, CLIA, and CAP certifications. Led by CEO Rohan (Ro) Hastie and based in Morrisville, NC, Metabolon positions itself as a global leader in metabolomics. The company intends to use recent financing to enhance growth initiatives, expand research and development, and further develop its metabolomics platform. It also plans to support global expansion, market penetration initiatives, and strategic partnerships. Metabolon is a Morrisville, NC-based provider of scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. Led by CEO Rohan (Ro) Hastie, the company serves research, diagnostic, therapeutic development, and precision medicine applications. Its offerings include a Global Discovery Panel enabled by a proprietary metabolomics reference library and scientific, technology, and bioinformatics techniques developed over more than 20 years. Metabolon reports completing 10,000+ projects and being cited in over 3,000 publications, and holds ISO 9001:2015 and CLIA certifications. The company recently raised $25M and intends to use the funds to accelerate commercialization activities and continue advancing its R&D roadmap. Metabolon provides scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management using its Precision Metabolomics™ Platform and proprietary reference library. Over more than 20 years the company has completed 10,000+ projects and contributed to 2,000+ publications, and holds ISO 9001:2015 and CLIA certifications. Its technology deciphers thousands of discrete chemical signals to reveal biological pathways and phenotype-level insights that other 'omics cannot. The company recently closed a $72 million combined debt and equity financing to support growth. Management says the incremental funding will accelerate growth, expand the client base, and fund R&D programs in machine learning for novel biomarker discovery and to expand its precision medicine platform. Metabolon also announced the appointment of Robert A. Cascella to its board alongside independent members Todd Schermerhorn and Jan Lundberg. Metabolon develops proprietary metabolomics platforms and informatics to deliver biomarker discoveries, diagnostic tests, and precision medicine products. The company plans to use the financing proceeds to further develop and commercialize its pipeline of precision medicine offerings based on its metabolomics technology. Metabolon serves clients across pharmaceutical, biotechnology, consumer products, agriculture, nutrition, academic, and government sectors. It has conducted more than 5,000 independent and collaborative studies and has over 600 peer-reviewed publications. Founded in 2000 and led by president and CEO John Ryals, Ph.D., the company is based in Research Triangle Park, N.C. Financially, Metabolon has raised approximately $80M to date and closed a new financing to support its commercialization efforts. Metabolon is a metabolomics firm in the precision medicine space that develops phenotyping technology to determine individual drug metabolism and response. Its core product uses metabolomics profiling to inform drug-response and precision-treatment decisions. The company announced a collaboration last year with Human Longevity Inc. According to a Wall Street Journal report, Metabolon generated about $25 million in revenue last year. It has been backed by roughly $50 million in private funding from investors including Aurora Funds Inc., Fletcher Spaght Ventures LP, Syngenta Ventures, Sevin Rosen Funds, Harris & Harris Group Inc., and Keating Capital Inc. Company representatives had not provided details on how the new funding will be used.

Total raised

$217M

Funding rounds

9

Latest round

Debt Financing

Latest activity

May 2024